Antisense oligonucleotides (ASOs) targeting mouse Angptl3 have been shown to slow atherosclerosis progression, reduce hepatic lipid accumulation, and lower plasma lipid levels, including total cholesterol, low-density lipoprotein cholesterol, and triglycerides in mice.41 In humans, ASOs targeting ANGPTL3 in clinical trials also reduces atherogenic lipoproteins,42 but ANGPTL3’s role in fructose metabolism has not previously been reported. This evidence concerns the gene ANGPTL3 and atherosclerosis.